Alethia’s pipeline places great emphasis on the development of monoclonal antibodies that were generated against therapeutic targets revealed using its integrated discovery and validation platform. A monoclonal antibody for the inhibition of cancer-associated epithelial-to-mesenchymal transition is currently being examined in animal models of invasive cancers. Furthermore, two monoclonal antibody lead candidates are under evaluation as inhibitors of osteoclast differentiation and tumor progression in our severe bone loss and ovarian cancer programs, respectively. Furthermore, Alethia has also obtained the rights on Isogranulatimide, a G2 checkpoint inhibitor which potentiates the response to several DNA-damaging chemotherapeutic agents which is in pre-clinical development.
